Positive News SentimentPositive NewsNASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis → How’d you do in 2022 (From Brooks Enterprises) (Ad) Free ABCL Stock Alerts $3.78 +0.03 (+0.80%) (As of 06/6/2024 ET) Add Compare Share Share Today's Range$3.72▼$3.8850-Day Range$3.63▼$4.7352-Week Range$3.58▼$8.05Volume1.20 million shsAverage Volume1.39 million shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$16.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AbCellera Biologics alerts: Email Address AbCellera Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside327.7% Upside$16.17 Price TargetShort InterestBearish9.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.60) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector396th out of 905 stocksPharmaceutical Preparations Industry183rd out of 430 stocks 3.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 1 research reports in the past 90 days.Read more about AbCellera Biologics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.58% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 15.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 3.3 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 1.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for AbCellera Biologics this week, compared to 2 articles on an average week.Search Interest20 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.60) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -7.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Brooks EnterprisesHow’d you do in 20222022 was a rough year. At their worst, the S&P 500 was down over 25% and the NASDAQ was down over 35%, and to make things even more interesting the Fed was seemingly raising interest rates every week!Get those kind of results during the Great Financial Crisis, without having to study more About AbCellera Biologics Stock (NASDAQ:ABCL)AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesMay 31, 2024 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest Down 15.2% in MayMay 28, 2024 | businesswire.comAbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024May 16, 2024 | markets.businessinsider.comKeyBanc Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)May 16, 2024 | seekingalpha.comAbCellera: If You Build It, Will They Come? Fresh Impetus RequiredMay 15, 2024 | seekingalpha.comAbCellera: Cash Providing Shelter From Market WeaknessMay 13, 2024 | investorplace.com3 Stock Gems Hiding in the NasdaqMay 10, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71May 8, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ICU Medical (ICUI), AbCellera Biologics (ABCL)May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbCellera Biologics on Strong Financials and Promising PartnershipsMay 8, 2024 | fool.comAbCellera Biologics (ABCL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comQ1 2024 Abcellera Biologics Inc Earnings CallMay 7, 2024 | investorplace.comABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comAbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss EstimatesMay 7, 2024 | businesswire.comAbCellera Reports Q1 2024 Business ResultsMay 6, 2024 | markets.businessinsider.comWhat Wall Street expects from AbCellera Biologics's earningsMay 2, 2024 | finance.yahoo.comInsider Stock Buying Reaches US$1.61m On AbCellera BiologicsMay 1, 2024 | businesswire.comAbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech CompaniesApril 18, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL)April 8, 2024 | businesswire.comAbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024April 3, 2024 | businesswire.comAbCellera to Report First Quarter 2024 Financial Results on May 7, 2024March 27, 2024 | investorplace.comThe 7 Best Penny Stocks to Buy in Q2 2024March 27, 2024 | finance.yahoo.comBillionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 StocksMarch 19, 2024 | businesswire.comAbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024March 11, 2024 | msn.comAbCellera gains on antibody collaboration with BiogenMarch 5, 2024 | businesswire.comAbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024See More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/06/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees586Year FoundedN/APrice Target and Rating Average Stock Price Target$16.17 High Stock Price Target$24.00 Low Stock Price Target$7.00 Potential Upside/Downside+327.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,400,000.00 Net Margins-410.47% Pretax Margin-471.19% Return on Equity-12.61% Return on Assets-9.79% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$38.03 million Price / Sales29.23 Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.95Miscellaneous Outstanding Shares294,050,000Free Float198,633,000Market Cap$1.11 billion OptionableOptionable Beta0.45 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 49)CEO, President & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 50)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 39)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 54)J.D., M.Sc., Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Comp: $644.4kMr. Neil Aubuchon B.A. (Age 53)M.B.A., Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Senior Director of Finance & AccountingDr. Ester Falconer Ph.D. (Age 49)Chief Technology Officer Kathleen Reid B.A.Head of Corporate CommunicationsGraham Craig M.Sc.Director of Corporate DevelopmentMr. Murray McCutcheon Ph.D.Senior Vice President of PartneringMore ExecutivesKey CompetitorsAlpine Immune SciencesNASDAQ:ALPNNuvalentNASDAQ:NUVLAlkermesNASDAQ:ALKSPerrigoNYSE:PRGOCrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInstitutional OwnershipWalleye Trading LLCSold 300 shares on 5/17/2024Ownership: 0.000%B. Riley Wealth Advisors Inc.Sold 9,000 shares on 5/16/2024Ownership: 0.004%Baker BROS. Advisors LPBought 4,615,887 shares on 5/15/2024Ownership: 9.361%Lazard Asset Management LLCSold 1,391,993 shares on 5/15/2024Ownership: 0.687%Nan Fung Group Holdings LtdBought 38,450 shares on 5/14/2024Ownership: 0.017%View All Institutional Transactions ABCL Stock Analysis - Frequently Asked Questions Should I buy or sell AbCellera Biologics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks. What is AbCellera Biologics' stock price target for 2024? 7 brokerages have issued 1 year target prices for AbCellera Biologics' shares. Their ABCL share price targets range from $7.00 to $24.00. On average, they predict the company's stock price to reach $16.17 in the next year. This suggests a possible upside of 327.7% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts. How have ABCL shares performed in 2024? AbCellera Biologics' stock was trading at $5.71 at the beginning of the year. Since then, ABCL stock has decreased by 33.8% and is now trading at $3.78. View the best growth stocks for 2024 here. Are investors shorting AbCellera Biologics? AbCellera Biologics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 19,750,000 shares, a decrease of 15.2% from the April 30th total of 23,290,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 14.6 days. Currently, 9.6% of the shares of the stock are sold short. View AbCellera Biologics' Short Interest. When is AbCellera Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ABCL earnings forecast. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) announced its earnings results on Tuesday, May, 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. The business had revenue of $9.95 million for the quarter, compared to analyst estimates of $10.73 million. AbCellera Biologics had a negative net margin of 410.47% and a negative trailing twelve-month return on equity of 12.61%. The company's revenue was down 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. What ETFs hold AbCellera Biologics' stock? ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include TrueShares Technology, AI & Deep Learning ETF (LRNZ).iShares Genomics Immunology and Healthcare ETF (IDNA). When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (9.36%), Baillie Gifford & Co. (7.92%), Lazard Asset Management LLC (0.69%), TrueMark Investments LLC (0.04%), Mirae Asset Global Investments Co. Ltd. (0.03%) and Duality Advisers LP (0.02%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABCL) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
